US Edition
Ozempic-like drug significantly reduces frequency of chronic migraines in pilot study
- Italian researcher Simone Braca and colleagues conducted a 12-week pilot study testing liraglutide on 31 obese patients with chronic migraines.
- The study arose because many migraine sufferers do not find relief with existing drugs and obesity is linked to increased migraine risk.
- Participants experienced an average reduction in migraine days from around 20 to 11 per month and one patient became completely migraine-free.
- The side effects like nausea and constipation were mild and resolved during the study, while researchers propose liraglutide reduced intracranial pressure causing symptom relief.
- Though preliminary and lacking a control group, the findings suggest GLP-1 receptor agonists could become valuable add-ons for difficult migraine cases, pending further research.
Insights by Ground AI
Does this summary seem wrong?
6 Articles
6 Articles
All
Left
3
Center
1
Right
2
Popular weight-loss drugs show promising new power against debilitating migraines
GLP-1 drugs show promise for migraine relief, reducing headache days from 20 to 11 per month in adults with obesity, with benefits appearing within two weeks regardless of weight loss.
·New York, United States
Read Full Article
Ozempic-like drug significantly reduces frequency of chronic migraines in pilot study
Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment options, some migraine sufferers cannot find relief in available drugs. Others experience side effects that prevent the use of certain available migraine medications.
Coverage Details
Total News Sources6
Leaning Left3Leaning Right2Center1Last UpdatedBias Distribution50% Left
Bias Distribution
- 50% of the sources lean Left
50% Left
L 50%
C 17%
R 33%
Factuality
To view factuality data please Upgrade to Premium
